Effect of metformin on cardiovascular risk factors in middle‐aged Thai women with metabolic syndrome: A randomized placebo‐controlled trial
สุชาดา อินทวิวัฒน์*, มณี รัตนไชยานนท์, Thanyarat Wongwananuruk, กิติรัตน์ เตชุไตรศักดิ์, Apiradee Jirattgalachote, Chongdee Dangrat
Gynecologic Endocrinology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
To evaluate the effect of metformin on cardiovascular risk factors in middle‐aged Thai women with metabolic syndrome that are in menopausal transition.
This study was double‐blind randomized placebo‐controlled trial. Metabolic syndrome was diagnosed using American Heart Association and National Heart, Lung, and Blood Institute criteria. After taking metformin 1700 mg/day for 6 months, cardiovascular risk factors were evaluated at baseline and month‐6; the values of which were used to calculate delta (Δ, month‐6 minus baseline values).
Forty menopausal participants were equally, randomized into either the placebo or metformin group. The two groups had comparable metabolic parameters at baseline, except that the mean triglyceride level was higher in the metformin group than in the placebo group. The significant improvements found only in the metformin group were body mass index, fasting blood glucose, high‐sensitivity C‐reactive protein and 10‐year risk of coronary heart disease (Framingham heart study) (P = 0.0004, P = 0.049, P = 0.035 and P = 0.029); whereas that only in the placebo group was high density lipoprotein cholesterol. However, there was no statistically significant difference in the improvement between the two groups.
Metformin can improve some parameters of metabolic syndrome in middle‐aged Thai women. Metformin is not superior to placebo for the improvement of cardiovascular risk factors.
Journal of Obstetrics and Gynaecology Research ปี 2563, July ปีที่: 46 ฉบับที่ 7 หน้า 1193-1202
Menopause, Metformin, Metabolic syndrome, ardiovascular disease